Related Experiment Video
Updated: Oct 10, 2026
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Medical therapy of unstable angina and non-Q-wave myocardial infarction
1Cardiology Division, University Hospital, University of New Mexico School of Medicine, Albuquerque 87131-5271, USA.
Insights
Acute coronary syndromes (ACS) management is evolving with new diagnostic markers like troponin and inflammation markers such as C-reactive protein (CRP). Risk stratification guides therapy, incorporating established and novel treatments like glycoprotein IIb/IIIa inhibitors.
Area of Science:
- Cardiology
- Biochemistry
- Internal Medicine
Background:
- Acute coronary syndromes (ACS) are a significant focus due to the high prevalence of unstable angina and non-Q-wave myocardial infarction (MI) in patients presenting with chest pain.
- Advancements in biochemical markers, including troponin and creatine kinase, have enhanced early diagnosis of myocardial necrosis.
- Inflammatory markers like C-reactive protein (CRP) show potential as early prognostic indicators, though not yet in widespread clinical use.
Purpose of the Study:
- To review the current management strategies for acute coronary syndromes.
- To highlight the role of risk stratification in guiding therapeutic interventions.
- To discuss established and emerging pharmacological therapies for ACS.
Main Methods:
- Review of current literature and clinical practice guidelines for acute coronary syndromes.
- Analysis of diagnostic markers, including biochemical and inflammatory markers.
- Evaluation of therapeutic interventions, encompassing both traditional and novel pharmacological agents.
Main Results:
- Risk stratification is crucial for tailoring medical therapies and determining the need for interventions like angiography or percutaneous coronary intervention (PCI).
- Established treatments (aspirin, heparin, nitrates, beta-blockers) are often used alongside or replaced by newer agents such as low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors.
- Hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) are under investigation for their potential role in ACS management.
Conclusions:
- Modern management of ACS relies on accurate diagnosis, risk stratification, and a combination of established and novel therapeutic approaches.
- Emerging therapies and markers are continually refining the treatment landscape for patients with acute coronary syndromes.
- Further research, particularly on statins, is needed to fully elucidate their role in ACS treatment.
Abstract:
Management of acute coronary syndromes has been the focus of increased interest in recent years. This has come about with the recognition that the majority of patients who present to the hospital with chest pain have unstable angina or non-Q-wave myocardial infarction (MI). Further, sensitive biochemical markers of myocardial necrosis, such as troponin and creatine kinase, have improved early diagnosis. Markers of inflammation such as C-reactive protein (CRP), although not in wide clinical practice, may provide an early and important marker of prognosis. The current approach to management of acute coronary syndromes is careful risk stratification so as to select appropriate medical therapies and to guide the clinician to appropriate interventions such as angiography or percutaneous coronary intervention (PCI). Established therapies such as aspirin, heparin, intravenous nitrates, and, in selected patients, beta blockers or calcium antagonists, are being used concomitantly with, or are being supplanted by, newer therapies such as low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors. The role of hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) in patients with acute coronary syndromes is being investigated and shows promise.
Related Concept Videos
01:26Angina IV: Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:20Angina V: Nursing Management
01:14Myocarditis III: Medical Management
01:27Coronary Artery Disease V: Interprofessional Care
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...